Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone

Haematologica

Volumn 97, Issue 6, 2012, Pages 937-942

  Persky, Daniel O ^a   Dornan, David ^b   Goldman, Bryan H ^c   Braziel, Rita M ^d   Fisher, Richard I ^e   LeBlanc, Michael ^c   Maloney, David G ^f   Press, Oliver W ^f   Miller, Thomas P ^a   Rimsza, Lisa M ^g  

^a UNIVERSITY OF ARIZONA   (United States)

^b GENENTECH INC   (United States)

^c Southwest Oncology Group Statistical Office   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

^g UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Chemotherapy; Combined monoclonal antibody; FCGR; Follicular lymphoma; SWOG

Indexed keywords

CD16 ANTIGEN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FC RECEPTOR IIA; FC RECEPTOR IIIA; METHOTREXATE; PREDNISONE; PROCARBAZINE; RITUXIMAB; TOSITUMOMAB; TOSITUMOMAB I 131; UNCLASSIFIED DRUG; VINCRISTINE;

ADULT; AGED; ALLELE; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); FEMALE; FOLLICULAR LYMPHOMA; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HUMAN TISSUE; MALE; PROGRESSION FREE SURVIVAL; PROTEIN POLYMORPHISM;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; FEMALE; GENOTYPE; HUMANS; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RECEPTORS, IGG; SURVIVAL ANALYSIS;

EID: 84862123411     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.050419     Document Type: Article

References (24)

1. http://www.gene.com/gene/products/ information/pdf/rituxan-prescribing.pdf.
2. Hilchey SP, Hyrien O, Mosmann TR, Livingstone AM, Friedberg JW, Young F, et al. Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab. Blood. 2009;113(16):3809-12.
3. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol. 2003;21(21):3940-7.
4. Sondermann P, Huber R, Oosthuizen V, Jacob U. The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex. Nature. 2000;406(6793):267-73.
5. Koene HR, Kleijer M, Algra J, Roos D, von dem Borne AE, de Haas M. Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood. 1997;90(3):1109-14.
6. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002;99(3):754-8.
7. Ghielmini M, Rufibach K, Salles G, Leoncini-Franscini L, Leger-Falandry C, Cogliatti S, et al. Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol. 2005;16(10):1675-82.
8. Boettcher S, Pott C, Ritgen M, Hiddemann W, Unterhalt M, Kneba M. Evidence for FcW receptor IIIA-independent rituximab effector mechanisms in patients with follicular lymphoma treated with combined immunochemotherapy. Blood (ASH Annual Meeting Abstracts). 2004;104:(Abstract 590).
9. Carlotti E, Palumbo GA, Oldani E, Tibullo D, Salmoiraghi S, Rossi A, et al. FcgammaRIIIA and FcgammaRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab. Haematologica. 2007;92(8): 1127-30.
10. Maloney D, Pender-Smith B, Unger J, Braziel R, Radich J, Press O, et al. FcBBreceptor polymorphisms do not influence progression free survival (PFS) of follicular NHL patients treated with CHOP followed by rituximab (SWOG 9800). Blood (ASH Annual Meeting Abstracts). 2004;104: (Abstract 589).
11. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53457-81.
12. Cox DR. Regression models and life-tables. JR Stat Soc [B]. 1972;34187-220.
13. Weng WK, Czerwinski D, Timmerman J, Hsu FJ, Levy R. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. J Clin Oncol. 2004;22(23): 4717-24.
14. Weng WK, Levy R. Immunoglobulin G Fc receptor polymorphisms do not correlate with response to chemotherapy or clinical course in patients with follicular lymphoma. Leuk Lymphoma. 2009;50(9):1494-500.
15. Pierz KA, Gu S, Lewis ME, Hsu S, Falandry C, Salles GA, et al. Predictive value of FCGR3A genotype on response to rituximab induction and maintenance therapy (MT) in follicular non-Hodgkin's lymphoma (NHL). J Clin Oncol. 2010;28;15s (suppl; asbtr 8065).
16. Ferris RL, Jaffee EM, Ferrone S. Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. J Clin Oncol. 2010;28(28):4390-9.
17. Veeramani S, Wang SY, Dahle C, Blackwell S, Jacobus L, Knutson T, et al. Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism. Blood. 2011;118(12): 3347-9.
18. Hatjiharissi E, Hansen M, Santos DD, Xu L, Leleu X, Dimmock EW, et al. Genetic linkage of Fc gamma RIIa and Fc gamma RIIIa and implications for their use in predicting clinical responses to CD20-directed monoclonal antibody therapy. Clin Lymphoma Myeloma. 2007;7(4):286-90.
19. Lejeune J, Thibault G, Ternant D, Cartron G, Watier H, Ohresser M. Evidence for linkage disequilibrium between Fcgamma RIIIa-V158F and Fcgamma RIIa-H131R polymorphisms in white patients, and for an Fcgamma RIIIa-restricted influence on the response to therapeutic antibodies. J Clin Oncol. 2008;26(33):5489-91.
20. Buchsbaum DJ, Wahl RL, Normolle DP, Kaminski MS. Therapy with unlabeled and 131I-labeled pan-B-cell monoclonal antibodies in nude mice bearing Raji Burkitt's lymphoma xenografts. Cancer Res. 1992; 52(23):6476-81.
21. Cardarelli PM, Quinn M, Buckman D, Fang Y, Colcher D, King DJ, et al. Binding to CD20 by anti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in Bcell lines. Cancer Immunol Immunother. 2002;51(1):15-24.
22. Radaev S, Motyka S, Fridman WH, Sautes-Fridman C, Sun PD. The structure of a human type III Fcgamma receptor in complex with Fc. J Biol Chem. 2001;276(19): 16469-77.
23. Kim DH, Jung HD, Kim JG, Lee JJ, Yang DH, Park YH, et al. FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. Blood. 2006;108(8):2720-5.
24. Wang J, Feng J, Zhang L, Hu Y, Luan B, Yue W, et al. Distribution of variant genotypes of Fc gamma receptor IIIa in healthy Chinese population of Zhengzhou City. J Huazhong Univ Sci Technolog Med Sci. 2003;23(3):239-41.